List of Excipients in Branded Drug QNASL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Respiratory LLC	QNASL	beclomethasone dipropionate	59310-406	ALCOHOL
Teva Respiratory LLC	QNASL	beclomethasone dipropionate	59310-406	NORFLURANE

QNASL Excipient Strategy and Commercial Opportunities in Nasal Allergy Treatment

Last updated: August 22, 2026

QNASL is a pressurized nasal aerosol containing beclomethasone dipropionate, ethanol, and hydrofluoroalkane 134a (HFA-134a). Its commercial differentiation comes from aerosol delivery rather than a complex excipient system. The main opportunities are lower-global-warming propellants, device compatibility, preservative-free nasal delivery, pediatric dose optimization, manufacturing partnerships, and lifecycle extensions based on formulation and delivery performance.

What excipients are used in QNASL?

QNASL uses a three-component formulation system:

Component	Function	Commercial relevance
Beclomethasone dipropionate	Active corticosteroid	Low-dose, poorly water-soluble nasal anti-inflammatory
Ethanol	Cosolvent and formulation aid	Supports drug solubilization and aerosol performance
HFA-134a	Propellant	Generates the metered nasal aerosol
Device components	Canister, metering valve, actuator	Control dose delivery, plume geometry, and deposition

QNASL is a solution aerosol rather than a conventional aqueous nasal suspension. The FDA label identifies the product as a nonaqueous nasal aerosol containing beclomethasone dipropionate in a propellant and ethanol system.[1]

The formulation contains no aqueous vehicle and does not rely on preservatives such as benzalkonium chloride. That characteristic can support positioning for patients who experience irritation or tolerability concerns with preservative-containing nasal sprays, although comparative clinical claims require supporting evidence.

Why does QNASL use ethanol and HFA-134a?

Beclomethasone dipropionate has limited water solubility. Ethanol acts as a cosolvent, allowing the drug to remain in solution with the propellant. HFA-134a provides the vapor pressure necessary for aerosolization and metered delivery.

The formulation is therefore dependent on the interaction among:

• Drug solubility in the ethanol-propellant system
• Ethanol concentration
• Propellant vapor pressure
• Valve metering volume
• Canister and valve compatibility
• Actuator geometry
• Temperature and storage conditions

Changes to any of these variables can alter emitted dose, spray pattern, plume geometry, droplet or particle-size distribution, actuator retention, and nasal deposition.

How does QNASL compare with aqueous nasal corticosteroids?

QNASL differs from leading aqueous nasal sprays primarily through its delivery platform.

Attribute	QNASL	Aqueous nasal corticosteroid spray
Dosage form	Pressurized nasal aerosol	Pump spray
Vehicle	Ethanol and HFA-134a	Water-based solution or suspension
Preservative requirement	No preservative identified in the formulation	May contain preservative, depending on product
Dose delivery	Metered aerosol valve and actuator	Metered mechanical pump
Drug state	Solution aerosol	Solution or suspension
Main formulation risk	Propellant, valve, and actuator performance	Suspension stability, pump performance, microbial control
Main environmental issue	HFA-134a global-warming potential	Lower propellant-related impact
Primary commercial differentiation	Aerosol plume and preservative-free delivery	Familiar spray format and lower device complexity

QNASL’s delivery format can offer a cleaner nasal sensation for some users because it avoids the larger aqueous spray volume associated with many pump products. The product also avoids the need to suspend micronized drug particles in water. Its disadvantages include greater device and manufacturing complexity and dependence on a fluorinated propellant.

What is the excipient strategy behind QNASL?

The strategy is functional minimalism. QNASL uses a small number of excipients, but each performs a critical role.

Solubility management

The ethanol-HFA system keeps beclomethasone dipropionate dissolved during filling, storage, actuation, and use. A reformulation that reduces ethanol must preserve solubility and prevent precipitation in the canister, valve, or actuator.

Potential development tools include:

• Cosolvent-ratio optimization
• Particle or surface characterization
• Drug concentration adjustment
• Alternative propellant screening
• Container closure compatibility studies
• Extractables and leachables testing

The commercial value of this work is high because the formulation cannot be treated independently from the delivery device.

Propellant management

HFA-134a is a mature pharmaceutical propellant with extensive regulatory precedent. It provides predictable pressure and has been used in metered-dose inhalation systems. Its limitation is environmental: HFA-134a has a high global-warming potential compared with newer hydrofluoroolefin propellants.

A next-generation QNASL-type product could investigate HFA-152a or HFO-1234ze. Such substitutions are not simple excipient replacements. They may affect:

• Vapor pressure
• Density
• Solubility
• Flammability
• Valve throughput
• Spray temperature
• Plume force
• Droplet evaporation
• Nasal deposition
• Canister pressure
• Transport and manufacturing controls

A propellant change would likely require a substantial chemistry, manufacturing, and controls package, device testing, stability data, and comparative performance studies. Depending on the extent of the change, FDA regulatory treatment could involve a supplement or a new application strategy.

Preservative avoidance

A nonaqueous, single-dose metered aerosol has a lower microbial-growth risk than an aqueous multidose nasal spray. That allows the product to avoid a conventional aqueous preservative system.

This creates a commercial opportunity for preservative-free nasal products in patients with:

• Chronic allergic rhinitis
• Repeated seasonal use
• Nasal dryness or irritation
• Sensitivity to excipients in aqueous sprays

The absence of a preservative does not eliminate the need for container closure, microbial limits, in-use stability, and manufacturing controls.

What formulations are protected by QNASL-related intellectual property?

QNASL-related protection is likely to involve the formulation, propellant system, metering device, actuator, and methods of treating allergic rhinitis. The commercially important claim categories are:

1. A beclomethasone dipropionate solution in HFA-134a and ethanol.
2. Specific drug, ethanol, and propellant concentration ranges.
3. Pressurized nasal aerosol containers and metering valves.
4. Actuator designs that control plume geometry and nasal deposition.
5. Methods for treating allergic rhinitis with specified dose strengths.
6. Pediatric dosing regimens and age-specific administration.
7. Manufacturing and filling processes for the aerosol formulation.

Patent strength depends on claim scope, expiration dates, terminal disclaimers, patent-term adjustment, prosecution history, and whether claims survive validity or infringement challenges. A formulation patent can create a barrier even after the basic active-ingredient patent expires, but its practical value depends on whether a competitor can use a different propellant, solvent ratio, concentration, or device.

Public product labeling identifies the QNASL active ingredient and excipients but does not, by itself, establish the complete patent estate or current enforceability of every patent associated with the product.[1] Orange Book status should be checked against the current FDA listing for the relevant NDA before making a launch or freedom-to-operate decision.[2]

When does QNASL lose exclusivity?

QNASL’s exclusivity position has two separate components:

• Regulatory exclusivity tied to the FDA approval pathway
• Patent exclusivity tied to issued claims and expiration dates

The FDA approved QNASL for allergic rhinitis in 2012. Its regulatory exclusivity periods are no longer the primary commercial barrier. The key remaining questions are patent scope, listed patents, pediatric exclusivity, litigation history, and the feasibility of designing around the aerosol formulation.[1][2]

A generic or authorized competitor would need to address more than beclomethasone dipropionate. It would need to match or justify differences in:

• Metered dose
• Delivered dose uniformity
• Spray content uniformity
• Priming and repriming
• Plume geometry
• Droplet-size distribution
• Device robustness
• Stability
• Local nasal tolerability

For a nasal aerosol, the device and formulation can create a more difficult development path than a conventional aqueous pump spray.

Are Paragraph IV challenges likely for QNASL?

A Paragraph IV applicant could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed. The most plausible attack points would be:

• Obviousness of the ethanol-HFA formulation
• Anticipation by earlier corticosteroid aerosol systems
• Lack of written description for broad concentration ranges
• Design-around using another propellant or solvent ratio
• Non-infringement through a different valve or actuator
• Failure of method-of-use claims to distinguish known allergic-rhinitis treatment

The strongest commercial defense would generally be claims that link formulation composition to measurable delivery performance. Broad claims covering only the presence of beclomethasone, ethanol, and HFA-134a may face greater validity and design-around pressure than claims tied to specific aerosol characteristics.

No current Paragraph IV litigation or settlement should be assumed without verification in FDA records, federal court dockets, and applicable company disclosures. Patent litigation involving a nasal aerosol would likely focus on claim construction, device ownership, bioequivalence methodology, and whether in vitro tests adequately establish pharmaceutical equivalence.

What generic launch scenarios exist for QNASL?

Scenario 1: Same formulation and device

A competitor attempts to replicate the ethanol-HFA solution and metered nasal aerosol. This route may offer the closest commercial profile but creates the highest risk of patent infringement and device-related regulatory complexity.

Scenario 2: Alternative propellant

A competitor uses a lower-global-warming propellant. This could avoid selected formulation claims and create a sustainability advantage, but it would require extensive compatibility, performance, safety, and stability work.

Scenario 3: Aqueous beclomethasone spray

A competitor launches an aqueous pump spray containing the same active ingredient. This may reduce device and propellant complexity but would not necessarily be substitutable for QNASL without a separate regulatory and clinical strategy.

Scenario 4: Authorized or branded alternative

The patent holder or a commercial partner launches a lower-cost version using the same or substantially similar formulation. This approach can protect channel access and reduce the incentive for an independent Paragraph IV launch.

What commercial opportunities exist in QNASL excipients?

Low-global-warming propellant supply

The largest excipient opportunity is replacement of HFA-134a with a lower-impact propellant. Suppliers with pharmaceutical-grade HFO or HFA capacity can pursue:

• Propellant qualification
• Stability packages
• Device compatibility
• Contract manufacturing
• Joint development with nasal aerosol developers

The principal barrier is not material availability. It is maintaining QNASL-equivalent delivery performance.

Excipient and device co-development

A supplier that provides only ethanol or propellant has limited differentiation. A stronger commercial position combines:

• Propellant supply
• Metering valve engineering
• Actuator design
• Canister coating
• Filling technology
• Analytical testing

This integrated model can produce switching costs and support formulation patents.

Pediatric and low-dose products

QNASL has 40 mcg and 80 mcg dose strengths. Pediatric products create opportunities for dose-count optimization, improved actuation ergonomics, and age-appropriate plume characteristics. Any pediatric reformulation must preserve dosing accuracy across repeated use and account for patient handling variability.[1]

International expansion

Geographic opportunities depend on local approval, patent status, propellant regulation, reimbursement, and availability of allergic-rhinitis products. A lower-global-warming formulation may be more valuable in jurisdictions that impose tighter controls on fluorinated propellants or promote sustainable pharmaceutical packaging.

International licensing could involve:

• Regional commercialization rights
• Local filling and packaging
• Device technology transfer
• Propellant supply agreements
• Co-development of a reformulated nasal aerosol

How strong is the QNASL patent estate?

The patent estate is strongest where formulation, device, and performance claims overlap. A competitor may be able to avoid one claim category but still encounter another involving the aerosol device or method of treatment.

Estate component	Likely barrier	Design-around potential
Active ingredient	Low for a long-marketed corticosteroid	High
Ethanol-propellant formulation	Moderate to high	Moderate
Metering valve and actuator	Moderate	Moderate
Spray-performance claims	High if narrowly defined	Moderate to high
Method-of-use claims	Moderate	High
Pediatric dosing claims	Variable	Moderate
Manufacturing process	Moderate	Moderate

The practical strength of QNASL protection therefore depends less on the active ingredient and more on the combination of formulation and delivery technology.

What FDA regulatory issues affect QNASL excipient opportunities?

FDA review would focus on pharmaceutical equivalence, device performance, product quality, and local safety. Relevant development areas include:

• Delivered-dose uniformity
• Spray-pattern testing
• Plume-geometry characterization
• Particle or droplet-size distribution
• Priming and repriming behavior
• In-use stability
• Extractables and leachables
• Leachables from valve elastomers
• Canister corrosion or coating integrity
• Ethanol and propellant assay
• Impurity and degradation-product control
• Local nasal toxicity
• Human factors for the actuator

For a reformulated product, the sponsor would need to establish that changes in excipients or device components do not produce clinically meaningful changes in exposure, deposition, local tolerability, or efficacy. FDA guidance on nasal spray development emphasizes product performance and device characterization rather than reliance on composition alone.[3]

What licensing deals could be attractive?

The most valuable licensing structures would link intellectual property with manufacturing capability. Attractive assets include:

1. A patent-protected low-global-warming propellant formulation.
2. A validated nasal aerosol valve and actuator platform.
3. A contract filling network for pressurized nasal products.
4. Regional rights to commercialize QNASL or a reformulated successor.
5. A preservative-free corticosteroid nasal delivery platform.
6. A pediatric nasal aerosol technology with dose-control data.

A royalty-bearing formulation license may be less defensible than an integrated agreement covering the propellant, device, analytical methods, and manufacturing process. Buyers will place greater value on assets that shorten development timelines and reduce regulatory comparability risk.

Key Takeaways

• QNASL uses beclomethasone dipropionate, ethanol, and HFA-134a in a pressurized nasal aerosol.
• Its formulation strategy is simple in composition but highly dependent on device and propellant performance.
• The most significant excipient opportunity is a lower-global-warming replacement for HFA-134a.
• Preservative-free delivery is a commercial differentiator against many aqueous nasal sprays.
• QNASL’s remaining competitive barriers are more likely to involve formulation, actuator, valve, and delivery-performance claims than the corticosteroid itself.
• Generic entry could occur through a replicated aerosol, alternative propellant, aqueous spray, or authorized alternative.
• The strongest licensing assets combine excipient technology with device engineering, filling, analytical methods, and patent protection.
• Current Orange Book listings, patent expirations, Paragraph IV notices, and litigation dockets must control any launch assessment.

FAQs About QNASL Excipient and Commercial Strategy

Does QNASL contain benzalkonium chloride?

The FDA label identifies beclomethasone dipropionate, ethanol, and HFA-134a as the formulation components and does not identify benzalkonium chloride.[1]

Could QNASL be reformulated with HFO-1234ze?

Potentially, but the change would require proof of equivalent or acceptable aerosol performance, stability, safety, device compatibility, and manufacturing control. It would not be a routine excipient substitution.

Is QNASL a suspension or solution nasal spray?

QNASL is a pressurized nasal aerosol formulated as a solution system rather than a conventional aqueous suspension.[1]

What is the main manufacturing barrier for QNASL?

The principal barrier is integrated control of the formulation, metering valve, actuator, canister, filling process, and emitted-dose performance.

Can a generic QNASL use a different propellant?

A generic applicant could pursue a different propellant, but the product would need to satisfy FDA requirements for pharmaceutical equivalence, device performance, quality, safety, and applicable patent obligations.

References

1. U.S. Food and Drug Administration. (2012). QNASL (beclomethasone dipropionate) nasal aerosol prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2002). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.